Steven Zeig

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

Anthony J. Bleyer, Steven K. Burke, Maureen Dillon et al. · American Journal of Kidney Diseases · 1999 · 277 citations

Hemodialysis, Urology, Renal Function +9

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Robert Provenzano, Anatole Besarab, Steven Charles Wright et al. · American Journal of Kidney Diseases · 2016 · 254 citations · Full text

Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia

Louis Holdstock, Amy M. Meadowcroft, Rayma Maier et al. · Journal of the American Society of Nephrology · 2015 · 189 citations

Hemodialysis Study, Dialysis Therapy, Pharmacotherapy +16

Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis

Julia B. Lewis, Mohammed Sika, Mark J. Koury et al. · Journal of the American Society of Nephrology · 2014 · 187 citations · Full text

Active Control Period, Hemodialysis, Urology +13